Abstract
Background Younger women have higher recurrent hospitalization rates and worse health status than men after their index episode of acute myocardial infarction (AMI). However, whether women have a higher risk of cardiovascular events in the year after discharge is unknown.
Methods We used data from the VIRGO (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients) study, which enrolled young AMI patients aged 18 to 55 years across 103 US hospitals. Sex differences in all-cause and cause-specific hospitalizations were compared by calculating incidence rates (IR, per 1,000 person-years) and incidence rate ratios (IRRs) with 95% confidence intervals (CIs). We then performed sequential modeling to evaluate the sex difference by calculating sub-distribution hazard ratios (SHR) accounting for deaths.
Results Among 2,007 women and 972 men, at least one all-cause hospitalization occurred among 905 (30.4%) participants in the year after discharge. The leading causes of hospitalization were MI-related (IR 171.8, 95% CI, 153.6-192.2 among women vs. IR 117.8, 95% CI, 97.3-142.6 among men), followed by non-cardiac (IR 145.8, 95% CI, 129.2-164.5 among women vs. IR 69.6, 95% CI, 54.5-88.9 among men) and other cardiac or stroke hospitalizations (IR 58.8, 95% CI, 48.8-70.7 among women vs. IR 53.8, 95% CI, 40.8-71.0 among men). Competing risk analysis showed that the sex difference was present for MI-related hospitalizations (SHR 1.33, 95%CI 1.04-1.70; P=0.02) and non-cardiac hospitalizations (SHR 1.51, 95%CI 1.13-2.07; P=0.01).
Conclusions Young women with AMI have more adverse outcomes compared with men in the year after discharge. MI-related hospitalizations were the most common cause of hospitalizations, but non-cardiac hospitalizations showed the most significant sex disparity. Further studies to better understand the underlying mechanisms of non-cardiac hospitalizations are warranted.
Competing Interest Statement
In the past three years, Harlan Krumholz received expenses and/or personal fees from UnitedHealth, Element Science, Aetna, Reality Labs, Tesseract/4Catalyst, F-Prime, the Siegfried and Jensen Law Firm, Arnold and Porter Law Firm, and Martin/Baughman Law Firm. He is a co-founder of Refactor Health and HugoHealth, and is associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare & Medicaid Services and through Yale University from Johnson & Johnson.
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT00597922
Funding Statement
The VIRGO study (NCT00597922) was supported by grant R01 HL081153 from the National Heart, Lung, and Blood Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review board approval was obtained at every 103 participating institutions in the VIRGO study (NCT00597922). Please refer to the individual sites as shown in the supplemental material.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding author.
Non-standard Abbreviations and Acronyms
- ACEi
- angiotensin-converting enzyme inhibitor
- AMI
- acute myocardial infarction
- ARB
- angiotensin receptor blocker
- ARIC
- Atherosclerosis Risk in Communities
- CABG
- coronary artery bypass graft
- CCB
- Calcium channel blocker
- CI
- confidence interval
- COPD
- chronic obstructive pulmonary disease
- CVD
- cardiovascular disease
- EQ-5D
- Euro QoL 5D
- ESSI
- ENRICHD Social Support Inventory
- ICD
- intracardiac defibrillator
- IR
- incidence rate
- IRR
- incidence rate ratio
- MI
- myocardial infarction
- MINOCA
- myocardial infarction with nonobstructive coronary arteries
- NSTEMI
- non-ST myocardial infarction
- PCI
- Percutaneous coronary intervention
- PHQ-9
- Patient Health Questionnaire
- POBA
- plain old balloon angioplasty
- SAQ
- Seattle Angina Questionnaire
- SD
- standardized difference
- SF-12
- Short Form-12
- SHR
- sub-distribution hazard ratio
- STEMI
- ST-elevated myocardial infarction
- VIRGO
- Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients
